The simvastatin (SV) used in this study was a generous gift from the Riyadh Pharma Co., Saudi Arabia. Low-molecular-weight
chitosan (viscosity 20,000 cps) (degree of deacetylation [DD] of 92%),
chondroitin 4-sulfate sodium salt (ChS, sodium content 5.6% w/w, molecular weight 59 kDa), simvastatin hydroxy acid ammonium salt sodium (SVA),
lovastatin,
lovastatin hydroxy acid sodium salt,
rhodamine B isothiocyanate (RBITC), and
carboxymethylcellulose were purchased from Sigma Aldrich Chemical Co. Ltd. (St. Louis, MO, USA). Sodium tripolyphosphate (TPP) and glacial acetic acid were obtained from BDH Organic (Poole, Dorset, UK). Ethanol,
methanol,
acetonitrile, and
phosphoric acid (HPLC grade) were obtained from Fisher Scientific Co., (Loughborough, UK). phosphate buffer solution (PBS) (pH 7.4) solution (8 g NaCl (137 mM), 0.2 g KCl (2.7 mM), 1.15 g Na
2HPO4··7H
2O (8.1 mM), and 0.2 g KH
2PO
4 (1.47 mM) in 1000 mL deionized water. Deionized water was obtained using a
Milli-Q® water purifier (Millipore, France) and used throughout the study.
Faris T.M., Harisa G.I., Alanazi F.K., Samy A.M, & Nasr F.A. (2020). Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability. Saudi Pharmaceutical Journal : SPJ, 28(12), 1851-1867.